Analysis of tissue lipidomics and computed tomography pulmonary fat attenuation volume (CTPFAV ) in idiopathic pulmonary fibrosis
© 2023 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology..
BACKGROUND AND OBJECTIVE: There is increasing interest in the role of lipids in processes that modulate lung fibrosis with evidence of lipid deposition in idiopathic pulmonary fibrosis (IPF) histological specimens. The aim of this study was to identify measurable markers of pulmonary lipid that may have utility as IPF biomarkers.
STUDY DESIGN AND METHODS: IPF and control lung biopsy specimens were analysed using a unbiased lipidomic approach. Pulmonary fat attenuation volume (PFAV) was assessed on chest CT images (CTPFAV ) with 3D semi-automated lung density software. Aerated lung was semi-automatically segmented and CTPFAV calculated using a Hounsfield-unit (-40 to -200HU) threshold range expressed as a percentage of total lung volume. CTPFAV was compared to pulmonary function, serum lipids and qualitative CT fibrosis scores.
RESULTS: There was a significant increase in total lipid content on histological analysis of IPF lung tissue (23.16 nmol/mg) compared to controls (18.66 mol/mg, p = 0.0317). The median CTPFAV in IPF was higher than controls (1.34% vs. 0.72%, p < 0.001) and CTPFAV correlated significantly with DLCO% predicted (R2 = 0.356, p < 0.0001) and FVC% predicted (R2 = 0.407, p < 0.0001) in patients with IPF. CTPFAV correlated with CT features of fibrosis; higher CTPFAV was associated with >10% reticulation (1.6% vs. 0.94%, p = 0.0017) and >10% honeycombing (1.87% vs. 1.12%, p = 0.0003). CTPFAV showed no correlation with serum lipids.
CONCLUSION: CTPFAV is an easily quantifiable non-invasive measure of pulmonary lipids. In this pilot study, CTPFAV correlates with pulmonary function and radiological features of IPF and could function as a potential biomarker for IPF disease severity assessment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Respirology (Carlton, Vic.) - 28(2023), 11 vom: 07. Nov., Seite 1043-1052 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
O'Callaghan, Marissa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 23.10.2023 Date Revised 25.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/resp.14582 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361401906 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361401906 | ||
| 003 | DE-627 | ||
| 005 | 20231226085048.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/resp.14582 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1204.xml |
| 035 | |a (DE-627)NLM361401906 | ||
| 035 | |a (NLM)37642207 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a O'Callaghan, Marissa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Analysis of tissue lipidomics and computed tomography pulmonary fat attenuation volume (CTPFAV ) in idiopathic pulmonary fibrosis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.10.2023 | ||
| 500 | |a Date Revised 25.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology. | ||
| 520 | |a BACKGROUND AND OBJECTIVE: There is increasing interest in the role of lipids in processes that modulate lung fibrosis with evidence of lipid deposition in idiopathic pulmonary fibrosis (IPF) histological specimens. The aim of this study was to identify measurable markers of pulmonary lipid that may have utility as IPF biomarkers | ||
| 520 | |a STUDY DESIGN AND METHODS: IPF and control lung biopsy specimens were analysed using a unbiased lipidomic approach. Pulmonary fat attenuation volume (PFAV) was assessed on chest CT images (CTPFAV ) with 3D semi-automated lung density software. Aerated lung was semi-automatically segmented and CTPFAV calculated using a Hounsfield-unit (-40 to -200HU) threshold range expressed as a percentage of total lung volume. CTPFAV was compared to pulmonary function, serum lipids and qualitative CT fibrosis scores | ||
| 520 | |a RESULTS: There was a significant increase in total lipid content on histological analysis of IPF lung tissue (23.16 nmol/mg) compared to controls (18.66 mol/mg, p = 0.0317). The median CTPFAV in IPF was higher than controls (1.34% vs. 0.72%, p < 0.001) and CTPFAV correlated significantly with DLCO% predicted (R2 = 0.356, p < 0.0001) and FVC% predicted (R2 = 0.407, p < 0.0001) in patients with IPF. CTPFAV correlated with CT features of fibrosis; higher CTPFAV was associated with >10% reticulation (1.6% vs. 0.94%, p = 0.0017) and >10% honeycombing (1.87% vs. 1.12%, p = 0.0003). CTPFAV showed no correlation with serum lipids | ||
| 520 | |a CONCLUSION: CTPFAV is an easily quantifiable non-invasive measure of pulmonary lipids. In this pilot study, CTPFAV correlates with pulmonary function and radiological features of IPF and could function as a potential biomarker for IPF disease severity assessment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a idiopathic pulmonary fibrosis | |
| 650 | 4 | |a interstitial lung disease | |
| 650 | 4 | |a lipidomics | |
| 650 | 4 | |a pulmonary fat | |
| 650 | 4 | |a quantitative CT | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Lipids |2 NLM | |
| 700 | 1 | |a Duignan, John |e verfasserin |4 aut | |
| 700 | 1 | |a Tarling, Elizabeth J |e verfasserin |4 aut | |
| 700 | 1 | |a Waters, Darragh K |e verfasserin |4 aut | |
| 700 | 1 | |a McStay, Megan |e verfasserin |4 aut | |
| 700 | 1 | |a O'Carroll, Orla |e verfasserin |4 aut | |
| 700 | 1 | |a Bridges, James P |e verfasserin |4 aut | |
| 700 | 1 | |a Redente, Elizabeth F |e verfasserin |4 aut | |
| 700 | 1 | |a Franciosi, Alessandro N |e verfasserin |4 aut | |
| 700 | 1 | |a McGrath, Emmet E |e verfasserin |4 aut | |
| 700 | 1 | |a Butler, Marcus W |e verfasserin |4 aut | |
| 700 | 1 | |a Dodd, Jonathan D |e verfasserin |4 aut | |
| 700 | 1 | |a Fabre, Aurelie |e verfasserin |4 aut | |
| 700 | 1 | |a Murphy, David J |e verfasserin |4 aut | |
| 700 | 1 | |a Keane, Michael P |e verfasserin |4 aut | |
| 700 | 1 | |a McCarthy, Cormac |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respirology (Carlton, Vic.) |d 1998 |g 28(2023), 11 vom: 07. Nov., Seite 1043-1052 |w (DE-627)NLM093444214 |x 1440-1843 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2023 |g number:11 |g day:07 |g month:11 |g pages:1043-1052 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/resp.14582 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2023 |e 11 |b 07 |c 11 |h 1043-1052 | ||